Contact Us

Atypical Antipsychotic Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Which atypical antipsychotic drug(s) did the patient take?

What condition was this medication prescribed to treat?

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Study Finds Hyperglycemia Linked to Antipsychotic Medications Validates Prior Research and Zyprexa Litigation Claims

Dec 1, 2005 |

A new study at the VA Connecticut Healthcare System, New Haven, Connecticut found that those taking atypical antipsychotic drugs may be at risk for developing high blood sugar (hyperglycemia).

The research, which was conducted by a team led by Dr. Michael J. Sernyak, monitored the frequency of undiagnosed high blood sugar in 647 patients taking various atypical antipsychotics, including: Clozaril (clozapine), Risperdal (risperidone), Zyprexa (olanzapine), Seroquel (quetiapine), or Geodon (ziprasadone). Over the course of two years, 153 of the participants had a fasting blood sugar result.

The study’s findings, published in the Journal of Clinical Psychiatry for December 2005, show that blood sugar levels were normal for 70% of the subjects, raised in 25% and extremely elevated in just over 5% of the participants.

Race, ethnicity, age, body mass index (BMI), or psychiatric diagnosis did not appear to have an impact on the development of high blood sugar.

Of all the antipsychotic medications, Clozaril was found to raise blood sugar in significantly more individuals than any of the other medications. The researchers did not find substantial differences for any of the other drugs.

According to the study, almost one in three patients taking atypical antipsychotics who thought their blood sugar levels were normal actually had abnormalities. The authors believe this finding should prompt the implementation of periodic screening even in large outpatient populations.

On June 10, reported that Eli Lilly had agreed to pay $690 million to settle some 8,000 claims regarding its failure to adequately warn patients that Zyprexa posed an increased risk of diabetes and hyperglycemia.

Specifically, the claims were based on allegations that prior to September 2003, Lilly failed to adequately warn those taking Zyprexa of an increased risk of developing diabetes, hyperglycemia, and related illnesses.

While the pharmaceutical giant did not admit its best-selling drug caused the injuries in question, its potential exposure in the litigation far exceeded the settlement figure. Thus, as a business decision, resolving about 75% of the claims six months before trial made sense.

At the time, Jerrold S. Parker, senior partner in the prominent New York personal injury law firm of Parker & Waichman, told reporters that: “It’s really remarkable to arrive at a settlement of this magnitude so far in advance of trial.”

Mr. Parker said that the plaintiffs’ litigation team, made up of some of the foremost products liability attorneys, “was able to convince Lilly that plaintiffs’ case was a strong one, with a good likelihood of success, if it proceeded to trial.                                 
The fund will be administered by a panel named by the plaintiffs’ attorneys which will allocate compensation to the plaintiffs based mostly on the extent of their injuries which range from weight gain to death.

Zyprexa, like two other powerful antipsychotic drugs, Risperdal (Jannsen Pharmaceuticals) and Seroquel (AstraZeneca), has been found to cause serious side effects in patients, especially those who have already been diagnosed with diabetes and related illnesses.

Knowledge of the dangers of Zyprexa was discovered as a result of a series of findings beginning in 2001 when the FDA was alerted to 19 case reports of diabetes associated with the drug.

One of these cases resulted in death due to necrotizing pancreatitis, a condition in which cells in the pancreas die. In May 2003, forty additional reports of hyperglycemia (elevated blood sugar), diabetes mellitus, or exacerbation of diabetes were received in the UK including one which proved to be fatal.

An emergency report issued by the Japanese Health and Welfare Ministry in April of 2002 concerning the side effects of Zyprexa noted that there had been two deaths of patients who had diabetes prior to taking the anti-psychotic medication. It also reported that there had been seven other patients who lost consciousness or slipped into comas after taking the drug.

In April of 2003, the Wall Street Journal ran a front page article on Zyprexa and other anti-psychotics and their link to the development of diabetes. The article estimated that somewhere around 11 million people have taken Zyprexa.

An eight-year study found that nearly 300 patients developed diabetes, 75 became seriously ill, and 23 died. Although the FDA was aware of these cases, it did not require Lilly (and the manufactures of similar antipsychotic drugs) to add a significant warning regarding these risks until September 2003.

Zyprexa has been prescribed to more than 17 million people worldwide since it was first marketed in 1996.  It became Lilly’s best selling medication, after Prozac lost U.S. patent protection in 2001, with annual sales of $4.4 billion or almost 33% of Lilly’s total sales of $13.86 billion.

The results of the newest study serve to confirm the findings reached in previous research as well as the validity of the claims that prompted Lilly’s settlement in June.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo